new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)


Similar
Filing Names

Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals Inc_20100128
Regeneron Pharmaceuticals Inc_20131212

Popular
Companies


Web
Adobe patents
Amazon patents
Apple patents
Ebay patents
Facebook patents
Google patents
IBM patents
Linkedin patents
Microsoft patents
Oracle patents
Red Hat patents
Yahoo patents

Food/Health
Adidas
Nike patents
Pfizer patents
Monsanto patents
Medtronic patents
Kraft patents

Transportation
Boeing patents
Tesla Motors patents

Telecom
Qualcomm patents
Motorola patents
Nokia patents
RIMM patents

Industrial/Electronics
AMD
Applied Materials
Seagate patents
General Electric
Caterpillar patents
Samsung
Wal-mart patents

  

Regeneron Pharmaceuticals Inc patents


      
Recent patent applications related to Regeneron Pharmaceuticals Inc. Regeneron Pharmaceuticals Inc is listed as an Agent/Assignee. Note: Regeneron Pharmaceuticals Inc may have other listings under different names/spellings. We're not affiliated with Regeneron Pharmaceuticals Inc, we're just tracking patents.

ARCHIVE: New 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "R" | Regeneron Pharmaceuticals Inc-related inventors




Count Application # Date Regeneron Pharmaceuticals Inc patents (updated weekly) - BOOKMARK this page
12016011524604/28/16  new patent  Methods for inhibiting atherosclerosis by administering an inhibitor of pcsk9
22016011548604/28/16  new patent  Nuclease-mediated dna assembly
32016011550204/28/16  new patent  Novel cho integration sites and uses thereof
42016010836004/21/16 Genetic modification of rats
52016010836904/21/16 Methods and compositions for generating or maintaining pluripotent cells
62016010056104/14/16 Non-human animals with modified immunoglobulin heavy chain sequences
72016010115204/14/16 Use of a vegf antagonist to treat angiogenic eye disorders
82016010118104/14/16 Process for reducing subvisible particles in a pharmaceutical formulation
92016010214704/14/16 Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
102016009705904/07/16 Enhanced expression and stability regions
112016009041003/31/16 Fucosylation-deficient cells
122016008131403/24/16 Chimeric antigen receptors
132016008346603/24/16 Anti-il-25 antibodies and uses thereof
142016007577203/17/16 Treatment of fibrodysplasia ossificans progressiva
152016007577803/17/16 Anti-glucagon antibodies and uses thereof
162016005797903/03/16 Human lambda light chain mice
172016006035903/03/16 Human lambda light chain mice
182016006065703/03/16 Methods and compositions for the targeted modification of a genome
192016005089602/25/16 Non-human animals having a humanized signal-regulatory protein gene
202016005298602/25/16 Humanized il-7 rodents
212016005328002/25/16 Efficient selectivity of recombinant proteins
222016004556602/18/16 Angiopoietin-based interventions for treating cerebral malaria
232016004696002/18/16 Methods and compositions for targeted genetic modifications and methods of use
242016003059102/04/16 Biologically active molecules, conjugates thereof, and therapeutic uses
252016003201502/04/16 Stabilized formulations containing anti-pcsk9 antibodies
262016003353002/04/16 Isolating cells expressing secreted proteins
272016002185601/28/16 Genetically modified t cell receptor mice
282016002414701/28/16 Purification platform for bispecific antibodies
292016002419501/28/16 Human antibodies to grem1
302016002420801/28/16 Human antibodies to nav1.7
312016001702901/21/16 Stabilized formulations containing anti-ngf antibodies
322016000757901/14/16 Humanized dipeptidyl peptidase iv (dpp4) animals
332016000233201/07/16 Anti-asic1 antibodies and uses thereof
342016000234101/07/16 Stabilized formulations containing anti-interleukin-6 receptor (il-6r) antibodies
352015037626712/31/15 Human antibodies to human delta like ligand 4
362015037626912/31/15 Human antibodies to serum resistance-associated protein from trypanosoma brucei rhodesiense
372015037662812/31/15 Nuclease-mediated dna assembly
382015037665012/31/15 Methods and compositions for modifying a targeted locus
392015037665112/31/15 Methods and compositions for targeted genetic modifications and methods of use
402015036617412/24/15 Non-human animals having a humanized programmed cell death 1 gene
412015036617512/24/15 Humanized il-15 animals
422015035137112/10/15 Hybrid light chain mice
432015035137212/10/15 Humanized dipeptidyl peptidase iv (dpp4) animals
442015035363412/10/15 Production cell line enhancers
452015034216312/03/15 Genetically modified major histocompatibility complex mice
462015033702911/26/15 Human antibodies to middle east respiratory syndrome - coronavirus spike protein
472015033704311/26/15 Anti-egfr antibodies and uses thereof
482015033704511/26/15 Human antibodies to the glucagon receptor
492015032752411/19/15 Genetically modified non-human animals expressing human epo
502015033099811/19/15 Vegf-a121 assay
512015033099911/19/15 Vegf-a121 assay
522015032002111/12/15 Humanized il-4 and il-4ra animals
532015032002211/12/15 Humanized il-4 and il-4ra animals
542015032002311/12/15 Human lambda light chain mice
552015031319311/05/15 Common light chain mouse
562015031319411/05/15 Humanized c5 and c3 animals
572015031319511/05/15 Low affinity fcgr deficient mice
582015029930310/22/15 Human antibodies to fel d1 and methods of use thereof
592015029930910/22/15 Production cell line enhancers
602015029931010/22/15 Production cell line enhancers
612015028948910/15/15 Non-human animals that make single domain binding proteins
622015029197810/15/15 Mirna-regulated differentiation-dependent self-deleting cassette
632015028246310/08/15 Non-human animals having humanized fc-gamma receptors
642015028447410/08/15 Anti-pcsk9 antibodies with ph-dependent binding characteristics
652015027209210/01/15 Humanized il-6 and il-6 receptor
662015026695709/24/15 Anti-prokineticin receptor (prokr) antibodies and uses thereof
672015026696609/24/15 Methods and antibody compositions for tumor treatment
682015026697609/24/15 Vl antigen binding proteins exhibiting distinct binding characteristics
692015025942309/17/15 Anti-egfrviii antibodies and uses thereof
702015025015109/10/15 Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
712015025210709/10/15 Aplnr modulators and uses thereof
722015024559809/03/15 Genetically modified major histocompatibility complex animals
732015024611909/03/15 Methods for treating or preventing asthma by administering an il-4r antagonist
742015024697309/03/15 Methods for treating skin infection by administering an il-4r antagonist
752015024697609/03/15 Hybrid light chain mice
762015024697709/03/15 Hybrid light chain mice
772015023123608/20/15 Methods for treating patients with hypercholesterolemia that is not adequately controlled by moderate-dose statin therapy
782015023254508/20/15 Human antibodies to human delta like ligand 4
792015020862207/30/15 Genetically modified non-human animals and methods of use thereof
802015021077607/30/15 Adam6 mice
812015020158907/23/15 Adam6 mice
822015020357907/23/15 Human antibodies to pd-1
832015020358007/23/15 Human antibodies to pd-l1
842015020359107/23/15 Mutivalent antigen-binding proteins
852015019601507/16/15 Mice that make heavy chain antibodies
862015019755307/16/15 Mice that make heavy chain antibodies
872015019755407/16/15 Mice that make heavy chain antibodies
882015019755507/16/15 Mice that make heavy chain antibodies
892015019755607/16/15 Mice that make heavy chain antibodies
902015019755707/16/15 Mice that make heavy chain antibodies
912015019756407/16/15 Anti-angptl3 antibodies and uses thereof
922015019757807/16/15 Anti-tie2 antibodies and uses thereof
932015019153407/09/15 Human antibodies to human delta like ligand 4
942015017333106/25/15 Human lambda light chain mice
952015017333206/25/15 Human lambda light chain mice
962015017567606/25/15 Fusion polypeptides capable of activating receptors
972015017568806/25/15 Production cell line enhancers
982015017600206/25/15 Human lambda light chain mice
992015016559806/18/15 Devices and methods for facilitating treatment of electrospray columns
1002015016664706/18/15 Antikine antibodies that bind to multiple cc chemokines
1012015016021506/11/15 Isolating cells expressing secreted proteins
1022015015217706/04/15 High affinity human antibodies to human angiopoietin-2
1032015015219106/04/15 Dosing regimens for use with pcsk9 inhibitors
1042015014734205/28/15 Methods for treating cancer by administering an anti-ang-2 antibody
1052015014000205/21/15 Use of a pcsk9 inhibitor to treat hyperlipidemia
1062015014355805/21/15 Non-human animals having a humanized b-cell activating factor gene
1072015014355905/21/15 Non-human animals having a humanized a proliferation-inducing ligand gene
1082015014356105/21/15 Non-human animals having a humanized b-cell activating factor gene
1092015014356205/21/15 Non-human animals having a humanized a proliferation-inducing ligand gene
1102015011955604/30/15 Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
1112015011075404/23/15 High resolution allele identification
1122015011080104/23/15 Human antibodies to gfr alpha 3 and methods of use thereof
1132015010573504/16/15 Syringe pistons, systems and methods
1142015010696104/16/15 Humanized il-15 animals
1152015009929604/09/15 Promoter-regulated differentiation-dependent self-deleting cassette
1162015010003004/09/15 Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
1172015008967803/26/15 Non-human animals having a humanized signal-regulatory protein gene
1182015008967903/26/15 Non-human animals having a humanized signal-regulatory protein gene
1192015008968003/26/15 Human lambda light chain mice
1202015007908703/19/15 Vegf antagonist formulations
1212015008246903/19/15 Humanized il-7 rodents
1222015006418903/05/15 Method of treating cancer with dll4 antagonist and chemotherapeutic agent
1232015006790103/05/15 Production of fertile xy female animals from xy es cells
1242015005622102/26/15 Anti-prlr antibodies and uses thereof
1252015005622202/26/15 Anti-prlr antibodies and uses thereof
1262015005900902/26/15 Methods for making fully human bispecific antibodies using a common light chain
1272015004706102/12/15 Humanized m-csf mice
1282015004706202/12/15 Lincrna-deficient non-human animals
1292015003733902/05/15 Anti-activin a antibodies and uses thereof
1302015004025302/05/15 Genetically modified major histocompatibility complex mice
1312015002441201/22/15 Humanized fcgammar mice
1322015001717601/15/15 Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor
1332015001718201/15/15 Methods for treating nasal polyposis by administering an il-4r antagonist
1342015002022401/15/15 Non-human animals with modified immunoglobulin heavy chain sequences
1352015001056801/08/15 Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and or activin a
1362015001302201/08/15 Humanized il-6 and il-6 receptor
1372015001302301/08/15 Humanized il-6 and il-6 receptor
1382014035637012/04/14 Methods for treating autosomal dominant hypercholesterolemia associated with pcsk9 gain-of-function mutations
1392014035637112/04/14 Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (pcsk9)
1402014035637212/04/14 Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r inhibitor
1412014033134011/06/14 Methods and compositions for generating a mouse
1422014032221510/30/14 Methods of inhibiting tumor growth by antagonizing il-6 receptor
1432014031524910/23/14 Inducible eukaryotic expression system
1442014028987609/25/14 Mice that make heavy chain antibodies
1452014027164209/18/14 Il-33 antagonists and uses thereof
1462014027165309/18/14 Human antibodies to respiratory syncytial virus f protein and methods of use thereof
1472014027165809/18/14 Anti-il-33 antibodies and uses thereof
1482014027168109/18/14 High affinity human antibodies to human il-4 receptor
1492014027309509/18/14 Serum-free cell culture medium
1502014027548909/18/14 Apelin fusion proteins and uses thereof
1512014028315809/18/14 Rodents with conditional acvr1 mutant alleles
1522014025539009/11/14 Method of treating rheumatoid arthritis with an anti-il-6r antibody
1532014025541909/11/14 Method of treating stress hyperglycemia with human antibodies to the glucagon receptor
1542014025542909/11/14 Methods of treating autoimmune diseases with dll4 antagonists
1552014025599509/11/14 High affinity antibodies to human il-6 receptor
1562014024866409/04/14 Readily isolated bispecific antibodies with native immunoglobulin format
1572014024350408/28/14 Antibodies comprising chimeric constant domains
1582014024546608/28/14 Humanized t cell co-receptor mice
1592014024546708/28/14 Genetically modified major histocompatibility complex mice
1602014024546808/28/14 Non-human animals with modified immunoglobulin heavy chain sequences
1612014022002308/07/14 Method of treating osteoarthritis with an antibody to ngf
1622014021377307/31/14 Adam6 mice
1632014019655007/17/14 Systems and devices for sample handling
1642014019976107/17/14 Promoter-regulated differentiation-dependent self-deleting cassette
1652014019340207/10/14 Anti-pdgfr-beta antibodies and uses thereof
1662014019459707/10/14 Modified chimeric polypeptides with improved pharmacokinetic properties
1672014018990007/03/14 Mirna-regulated differentiation-dependent self-deleting cassette
1682014017887906/26/14 Compositions and methods for modifying cells
1692014017990306/26/14 High affinity human antibodies to human protease-activated receptor 2
1702014015470106/05/14 Humanized fc gamma r mice
1712014015568906/05/14 Methods of modifying genes in eukaryotic cells
1722014015744506/05/14 Low affinity fcgr deficient mice
1732014013797805/22/14 System and methods for use in dispensing biopharmaceutical materials
1742014013416905/15/14 Methods of treating ovarian cancer with dll4 antagonists
1752014013418905/15/14 Anti-prokineticin receptor (prokr) antibodies and uses thereof
1762014013471905/15/14 Recombinant cell surface capture proteins
1772014013727505/15/14 Hybrid light chain mice
1782014013019305/08/14 Mice that make vl binding proteins
1792014013019405/08/14 Mice that make vl binding proteins
1802014012010905/01/14 Human antibodies to human tnf-like ligand 1a (tl1a)
1812014011293004/24/14 Methods for treating or preventing malaria by administering an antibody that specifically binds angiopoietin-2 (ang-2)
1822014009931204/10/14 Methods for treating hypercholesterolemia and reducing ldl-c using antibodies to pcsk9
1832014008829503/27/14 Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof
1842014008276003/20/14 Non-human animals expressing ph-sensitive immunoglobulin sequences
1852014007256303/13/14 Methods and compositions comprising a combination of an anti-erbb3 antibody and an anti-egfr antibody
1862014007258303/13/14 Methods for treating atopic dermatitis by administering an il-4r antagonist
1872014007297903/13/14 Isolating cells expressing secreted proteins
1882014007298003/13/14 Isolating cells expressing secreted proteins
1892014007301003/13/14 Methods of modifying eukaryotic cells
1902014007558603/13/14 Parental cell lines for making cassette-free f1 progeny
1912014005690302/27/14 Human antibodies to gfr alpha 3 and methods of use thereof
1922014005690702/27/14 Anti-asic1 antibodies and uses thereof
1932014004473002/13/14 Anti-pcsk9 antibodies with ph-dependent binding characteristics
1942014004106802/06/14 Methods of modifying eukaryotic cells
1952014003333601/30/14 Methods of modifying eukaryotic cells
1962014003333701/30/14 Methods of modifying eukaryotic cells
1972014002363701/23/14 Methods of modifying eukaryotic cells
1982014001722801/16/14 Humanized light chain mice
1992014001722901/16/14 Methods of modifying eukaryotic cells
2002014001723801/16/14 Methods of modifying eukaryotic cells
2012014001769501/16/14 Isolating cells expressing secreted proteins
2022014001778101/16/14 Methods of modifying eukaryotic cells
2032014001778201/16/14 Methods for modifying eukaryotic cells
2042014001852201/16/14 Methods of modifying eukaryotic cells
2052014002012401/16/14 Methods of modifying eukaryotic cells
2062014002012501/16/14 Methods of modifying eukaryotic cells
2072014001345601/09/14 Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
2082014001345701/09/14 Methods of modifying eukaryotic cells
2092013034453812/26/13 Human antibodies to the glucagon receptor
2102013034010412/19/13 Humanized il-7 rodents
2112013033305712/12/13 Humanized non-human animals with restricted immunoglobulin heavy chain loci
2122013032326012/05/13 Stabilized formulations containing anti-dll4 antibodies
2132013032326112/05/13 Purified antibody composition
2142013032378812/05/13 Production cell line enhancers
2152013032379012/05/13 Human lambda light chain mice
2162013032379112/05/13 Restricted immunoglobulin heavy chain mice
2172013032664712/05/13 Human lambda light chain mice
2182013030967011/21/13 Nuclease-mediated targeting with large targeting vectors
2192013031212811/21/13 Promoter-regulated differentiation-dependent self-deleting cassette
2202013031212911/21/13 Promoter-regulated differentiation-dependent self-deleting cassette
2212013029509711/07/13 Human antibodies to fel d1 and methods of use thereof
2222013028075810/24/13 Fusion polypeptides capable of activating receptors
2232013027307010/17/13 Methods for treating or preventing influenza virus infection by administering a serine protease inhibitor
2242013026657410/10/13 Human antibodies to human angiopoietin-like protein 4
2252013025987610/03/13 Anti-hla-b*27 antibodies and uses thereof
2262013025988110/03/13 Fusion polypeptides capable of activating receptors
2272013026105610/03/13 Vegf antagonist formulations
2282013025172809/26/13 Method of treating stress hyperglycemia with human antibodies to the glucagon receptor
2292013025491109/26/13 Adam6 mice
2302013024377509/19/13 Multispecific antigen-binding molecules and uses thereof
2312013024378409/19/13 Methods for reducing lipoprotein(a) levels by administering an inhibitor of proprotein convertase subtilisin kexin-9 (pcsk9)
2322013024723409/19/13 Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
2332013024723509/19/13 Mice that produce antigen-binding proteins with ph-dependent binding characteristics
2342013024723609/19/13 Non-human animals expressing ph-sensitive immunoglobulin sequences
2352013023053109/05/13 Human antibodies to clostridium difficile toxins
2362013023053309/05/13 Methods of treating systemic lupus erythematosus (sle) using anti-cd48 antibodies
2372013021654708/22/13 Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
2382013020949208/15/13 Anti-tie2 antibodies and uses thereof
2392013021013708/15/13 Methods of modifying eukaryotic cells
2402013021271908/15/13 Humanized rodents that express heavy chain containing vl domains
2412013019587808/01/13 Anti-asic1 antibodies and uses thereof
2422013019887908/01/13 Humanized universal light chain mice
2432013019888008/01/13 Mice expressing a limited immunoglobulin light chain repertoire
2442013018679707/25/13 Stabilized formulations containing anti-ang2 antibodies
2452013018927707/25/13 Stabilized formulations containing anti-pcsk9 antibodies
2462013018420507/18/13 Antitumor combinations containing a vegf-inhibiting agent and 5fu or a derivative thereof
2472013018581907/18/13 Genetically modified major histocompatibility complex animals
2482013018582007/18/13 Genetically modified major histocompatibility complex animals
2492013018582107/18/13 Common light chain mouse



ARCHIVE: New 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Regeneron Pharmaceuticals Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Regeneron Pharmaceuticals Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###